AC Bioscience

Executive Summary

AC Bioscience is a Swiss private biotech company founded in 2016, focused on developing novel small-molecule cancer therapies that target metabolic vulnerabilities in tumors. The company operates in the emerging field of cancer metabolism, aiming to exploit differences in metabolic pathways between cancer cells and normal cells. While specific pipeline details are not publicly disclosed, the company's approach aligns with a growing interest in precision oncology. Despite limited public information, AC Bioscience's location in the Lausanne biotech hub and focus on metabolic targets position it within a competitive but promising niche. However, as a private firm with no disclosed funding rounds or partnerships, the company is likely at an early stage, potentially preclinical. The low availability of data constrains a high conviction assessment, but the scientific rationale and unmet need in cancer metabolism warrant cautious optimism.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND-enabling studies completion40% success
• Q2 2027Series A funding round announcement30% success
• Q1 2028First-in-human clinical trial initiation20% success